RGS receives Innovation Grant
The grant has been awarded to the Company under the Department's Entrepreneurs' Programme for Regeneus' study with Monash University, which explores the mode of action of mesenchymal stem cells (MSCs) in pain management. The funding matches Regeneus' project spending over 12 months.
The Innovation Connections Grant aims to help collaboration between businesses and research organisations to develop and implement new ideas with commercial potential.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.